OncoHelix

OncoHelix is proud to announce our partnership with Qualisure Diagnostics Inc. to bring the Thyroid GuidePx® test to patients across Canada. 🎉 This advanced genomic tool leverages next-generation sequencing to guide personalized treatment strategies for papillary thyroid cancer, enhancing patient outcomes and improving quality of life.   Through this partnership, Thyroid GuidePx® testing will be performed at OncoHelix’s clinically accredited laboratory in Calgary, ensuring precision, reliability, and accessibility for thyroid cancer patients across the country.   🚀 Learn more about this impactful collaboration and how OncoHelix and Qualisure Diagnostics, together, are transforming cancer diagnostics by reading the full press release here: https://lnkd.in/dJeWEE5n Faisal Masood Khan Pinaki Bose Kevin James Oliver Bathe Cynthia Stretch, PhD Sally Abou-Zeki, MBA Dave Ehman P.Eng., CISSP Burjeel Holdings Prof.Humaid Al-Shamsi MB(IRL),FRCP(Lon),FRCP(Ca),FRCP(Glasgow),FACP(US)Philip Shabo BSc, MSc 🇬🇧 🇦🇪 Dr. Rawia Mohamed #OncoHelix #PrecisionOncology #CancerDiagnostics #ThyroidCancer #BetterInsights #BetterHealth

The OncoHelix team is in the Christmas spirit!! 🎄 Wishing everyone a joyful season of hope, happiness, and health.⭐ Faisal Masood Khan Poonam Dharmani-Khan Pinaki Bose Mataya Van Heyst Amanjot Kaur Nazanin Vaziri Sapna Sharma Stephanie Dookie #OncoHelix #BetterInsights #BetterHealth

🚀 We are excited to share that Dr. Rehan Faridi, Director of Molecular Diagnostics, and Dr. Pinaki Bose, EVP of OncoHelix, recently attended the Association for Molecular Pathology (AMP) 2024 Annual Meeting & Expo, kindly invited by Roche. 🧬Dr. Faridi presented the significance of Homologous Recombination Deficiency (HRD) and OncoHelix’s real-world clinical experience with the Avenio Tumor Comprehensive Genomic Profiling (CGP) Kit—a groundbreaking test that OncoHelix is proud to be the only provider in Canada to offer clinically. He was joined by Dr. Eric Thompson and Dr. Muriel De Vos to share critical insights into the role of genomic technologies in oncology research in their respective laboratories. We would like to thank Roche Diagnostics staff Andi Broka amd Sunandini Chopra for their support. OncoHelix is proud to advance precision diagnostics and empower oncologists with cutting-edge tools to improve patient outcomes and will continue to participate in such important dialogues. #OncoHelix #precisiononcology #genomics #innovation

🚀 We are excited to share that Dr. Faisal Masood Khan, CEO of OncoHelix, was invited to attend and speak at the prestigious 3rd Emirates Pediatric Bone Marrow Transplant & Gene Therapy Congress, held in Abu Dhabi on November 9-10, 2024. Dr. Khan’s presentation, "Early and Accurate Prediction of AML Relapse after Allogenic HCT—A Tale of Two Contrasting Molecular Approaches," highlighted innovative strategies in precision medicine that are redefining outcomes in pediatric care.🔬 🌟This congress, endorsed by the Pediatric Diseases Working Party of the European Blood and Marrow Transplantation (The EBMT) brought together leading global experts to celebrate the successes of saving children worldwide. OncoHelix is proud to contribute to this international dialogue, celebrating Global Collaboration in Pediatric Care. #OncoHelix #PrecisionMedicine #PediatricCare

🚀 OncoHelix is proud to have participated in Alberta Precision Medicine Day which brought together leading minds in oncology to discuss the evolving landscape of precision oncology in Alberta. This event was hosted at the Bow Tower in Calgary by our EVP, Dr. Pinaki Bose, in his role as POET (Precision Oncology and Experimental Therapeutics) Co-Chair, alongside Dr. Steve Yip. 🧬 Our CEO, Dr. Faisal Masood Khan, also participated in the Panel Discussion: Provincial Perspective on AB Readiness for Implementing Precision Oncology with experts Dr. Steven Jones, Dr. Adrian Box, Dr. Renee Perrier, and Dr. Janessa Laskin. Dr. Khan also presented OncoHelix's perspective on the Current State of Oncology Biomarker Testing in AB and engaged in a concluding discussion on Alberta’s readiness to implement Precision Oncology. We are incredibly proud to be part of these pivotal conversations, driving progress in precision oncology and strengthening Alberta’s healthcare landscape! #OncoHelix #Oncology #ABHealth #PrecisionOncology #Alberta

🚀 OncoHelix is proud to have participated in Alberta Precision Medicine Day which brought together leading minds in oncology to discuss the evolving landscape of precision oncology in Alberta. This event was hosted at the Bow Tower in Calgary by our EVP, Dr. Pinaki Bose, in his role as POET (Precision Oncology and Experimental Therapeutics) Co-Chair, alongside Dr. Steve Yip. 🧬 Our CEO, Dr. Faisal Masood Khan, also participated in the Panel Discussion: Provincial Perspective on AB Readiness for Implementing Precision Oncology with experts Dr. Steven Jones, Dr. Adrian Box, Dr. Renee Perrier, and Dr. Janessa Laskin. Dr. Khan also presented OncoHelix's perspective on the Current State of Oncology Biomarker Testing in AB and engaged in a concluding discussion on Alberta’s readiness to implement Precision Oncology. We are incredibly proud to be part of these pivotal conversations, driving progress in precision oncology and strengthening Alberta’s healthcare landscape! #OncoHelix #Oncology #ABHealth #PrecisionOncology #Alberta

Happy Diwali from the OncoHelix team! 🪔✨ May this Diwali bring you and your family peace, good health, and happiness. 🌟Wishing everyone who celebrates a joyous Festival of Lights!🌟

🚨 Join us for the 2024 Precision Oncology and Experimental Therapeutics (POET) International Congress on November 7-8, 2024 at the magnificent Bow Tower in Calgary! OncoHelix is excited to announce that our EVP, Dr. Pinaki Bose, Scientific Lead for the POET Program at the University of Calgary, will be hosting this prestigious event alongside Dr. Steve Yip, POET Medical Lead. This two-day congress will bring together top minds in precision oncology to explore cutting-edge advancements in cancer treatment. 🌟 🔑The congress is a CME-accredited learning event. Learning Objectives: ~Learn to identify novel polyomic interrogatives to optimize treatment approaches with immunotherapeutics and targeted agents in cancer management. ~Gain insight into the design of precision oncology clinical trials. ~Understand key challenges in adopting precision oncology in traditional healthcare systems. 🔗 Register today: https://poet-calgary.ca/ Don't miss out on this opportunity to be at the forefront of cancer research and precision oncology! #PrecisionOncology #CancerResearch #Immunotherapy #TargetedTherapies #OncoHelix #POETCongress2024

🚀Exciting news! OncoHelix's EVP, Dr. Pinaki Bose, was invited to speak at the Emirates Oncology Society Annual Conference 2024 held from 4th-6th October in UAE. He shared insights into how OncoHelix is advancing precision oncology and expanding access to molecular and genomic testing across the UAE and the MENA region. 🌍 🧬EOS 2024 brought together a multidisciplinary tumour board with leading local, regional, and international experts from around the globe, covering key topics such as solid tumours, malignant hematology, palliative care, and more. We're proud to be part of the conversation shaping the future of oncology! Burjeel Holdings Prof.Humaid Al-Shamsi MB(IRL),FRCP(Lon),FRCP(Ca),FRCP(Glasgow),FACP(US) Marwan Ghosn Hassan Shahryar Sheikh Asif Irfan Philip Shabo BSc, MSc 🇬🇧 🇦🇪 Faisal Masood Khan Rehan Faridi Poonam Dharmani-Khan #PrecisionDiagnostics #Oncology #EOS2024 #OncoHelix

💝October is Breast Cancer Awareness Month, a time to highlight the advances in breast cancer research and the innovative strategies that are transforming patient care. A recent review published by Nature Magazine Reviews Clinical Oncology emphasizes the evolving landscape of treatments for advanced-stage hormone receptor-positive (HR+) breast cancer, particularly in overcoming resistance to current therapies. One of the most promising tools in this field is circulating tumor DNA (ctDNA), which allows for the early detection of resistance mutations before clinical progression without the need for invasive sampling. 🧬At OncoHelix we are proud to offer advanced molecular profiling that empowers oncologists with the insights needed for precision therapeutics. Our liquid biopsy solution utilizes MSK-ACCESS®, a ctDNA panel, powered with SOPHiA DDM™ (SOPHiA GENETICS) to help identify genomic alterations, including ESR1 mutations and other critical markers, ensuring that patients receive the most effective, tailored treatments based on their unique tumor profiles. This Breast Cancer Awareness Month, let’s continue to advocate for precision medicine and personalized care to help improve outcomes for those battling breast cancer. 🎀 Read the Review here: https://lnkd.in/diwZvdTA #breastcancerawarenessmonth #liquidbiopsy #ctDNA #OncoHelix